AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guselkumab 100 mg
Description: 100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for guselkumab
Description: Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for guselkumab
Description: Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
Study NCT02369900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
Study NCT02207244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for adalimumab
Description: Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
Study NCT01925937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT02424006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHCIII-MPC cornea
Description: Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
Study NCT02424006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Donor cornea
Description: Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
Study NCT04700436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
Description: IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
Study NCT01925937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT01925937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Study NCT01925937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for coenzyme Q10
Study NCT02131207 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance imaging
Description: Undergo pelvic MRI
Study NCT04700436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)
Description: IP~* Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)~* Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)
Study NCT02035579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training Intervention
Study NCT02035579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Intervention
Study NCT04507776 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Patients with spondyloarthrosis as provided in real world practice
Study NCT04255017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abidol hydrochloride
Description: Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
Study NCT04255017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
Study NCT04255017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
Study NCT04003181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Ciprofloxacin or Rifaximin for 10 days.
Study NCT04003181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bile Acid Binder
Description: Cholestyramine or Colesevelam lifelong.
Study NCT01753830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane
Description: 4.5 mL
Study NCT01753830 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: 4.5 mL
Study NCT00393068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib
Study NCT00393068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT00393068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel
Study NCT00393068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT00393068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU
Study NCT00393068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy
Study NCT00393068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study NCT01697852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with bendiocarb
Description: 2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
Study NCT01697852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LLIN by universal coverage campaign
Description: Long lasting Insecticide treated mosquito net
Study NCT01697852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLIN by universal coverage campaign
Description: Long lasting Insecticide treated mosquito net
Study NCT01322451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 fumarate
Description: single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
Study NCT01322451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 free base
Description: single oral dose, GLPG0259, 50 mg solid formulation
Study NCT01081535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac, fentanyl
Description: intravenous PCA
Study NCT05638958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate post-extractive Implant placement
Description: Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
Study NCT05638958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate post-extractive Implant placement
Description: Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
Study NCT02605356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02605356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Study NCT02605356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02605356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Study NCT02605356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03864146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Treatment
Description: This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
Study NCT03864146 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Behavioral Compliance Enhancement Treatment
Description: This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
Study NCT00845247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse case management
Description: Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
Study NCT02341651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
Study NCT02652910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19.CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express CD19-specific CARs
Study NCT03345446 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
Study NCT03339310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer Smart System with 2-leads
Description: The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
Study NCT04439864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyIDEA
Description: An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
Study NCT03272087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VATS (thoracoscopy)
Description: 50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
Study NCT03055702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminder
Description: an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
Study NCT01763684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signature Custom Guides
Description: Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
Study NCT01763684 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Traditional partial knee arthroplasty without the use of Signature technology.
Study NCT00131378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ growth hormone
Description: Participants will give themselves injections of growth hormone every night for 6 months.
Study NCT00131378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone
Description: Participants will give themselves injections of placebo growth hormone every night for 6 months.
Study NCT02131207 — intervention group
Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: Undergo prostate biopsy
Study NCT00636103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUF2
Description: 0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months
Study NCT02608151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with oil
Description: Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
Study NCT02608151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage without oil
Study NCT03823495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week PAP
Description: It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
Study NCT01950234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: Acthar gel
Study NCT01950234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01289444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily CEntered (FACE) ACP
Description: Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
Study NCT01289444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides.
Study NCT00636103 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months
Study NCT02373748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioGaming YuGo System
Description: Subjects will perform a customized training program predefined in the BioGaming YuGo system.
Study NCT04870138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
Study NCT04870138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
Study NCT04870138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
Study NCT04870138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA1090 A26
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
Study NCT04870138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA7527
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.